Drug intelligence / Profile preview

IRX211

Development stage: Unknown
Lead developer: InhaleRx
Modality: Small Molecules
Administration: Inhalation

Overview

IRX211 is a novel drug-device combination product consisting of a fixed dose of dronabinol (delta-9-tetrahydrocannabinol) delivered via a pressurized metered-dose inhaler (pMDI). Developed by InhaleRx, it is designed to provide rapid onset of action for the treatment of complex regional pain syndrome (CRPS) and potentially panic disorder. By utilizing the inhalation route, IRX211 aims to bypass first-pass metabolism and offer a more predictable pharmacokinetic profile compared to oral cannabinoid formulations. It is currently being evaluated in Phase 1 clinical trials to assess safety and pharmacokinetics in healthy volunteers, following the FDA's 505(b)(2) regulatory pathway.

Other names: dronabinol inhalation

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on IRX211.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IRX211.

Explore the full profile